International Journal of Hematology

, Volume 106, Issue 1, pp 135–137 | Cite as

First case report of hemophilia B Leyden in Japan

  • Atsuki YamashitaEmail author
  • Chiai Nagae
  • Mika Mori
  • Tomoko Ashikaga
  • Tetsuhito Kojima
  • Masashi Taki
Case Report


Hemophilia B Leyden is a unique subtype of hemophilia B, characterized by increasing factor IX activity (FIX:C) after puberty and a lower normal range of FIX:C throughout adulthood. However, to date, no Japanese case has been reported. Here, we report a case of hemophilia B Leyden in a 22-year-old male. He suffered from subgaleal hematoma, and was subsequently diagnosed with hemophilia B (FIX:C 0.2%) in the neonatal period. Both his parents are Japanese. There was no history of hemophilia in his family. FIX:C gradually increased with age (8% at age = 1; 14% at age = 7; 19% at age = 12; 32% at age = 18). FIX:C is within the range 30–40% in recent several years. He once required administration of FIX concentrate against traumatic tongue bleeding at 7 years of age. Genotyping analysis of FIX was performed after informed consent at 21 years of age, and a point mutation (c.–35G>A) was detected. This mutation has been reported previously as the Leyden mutation. Although it has been reported that hemophilia B Leyden is seen in 1.9% of patients with hemophilia B, the present case is the first report of hemophilia B Leyden from Japan.


Hemophilia B Leyden mutation Japanese 


Compliance with ethical standards

Conflict of interest

The authors stated that they do not have any conflict of interest with respect to the content of the manuscript.


  1. 1.
    Funnell AP, Wilson MD, Ballester B, Mak KS, Burdach J, Magan N, et al. A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am J Hum Genet. 2013;92:460–7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Radic CP, Rossetti LC, Abelleyro MM, Candela M, Perez Bianco R, de Tezanos Pinto M, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost. 2013;109:24–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost. 2013;11:1329–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Japan Foundation for AIDS Prevention. Project entrusted by Ministry of Health, Labour and Welfare. Nationwide Survey on Coagulation Disorders 2015. Published by Japan Foundation for AIDS Prevention, Tokyo.Google Scholar
  5. 5.
    Veltkamp JJ, Meilof J, Remmelts HG, van der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol. 1970;7:82–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Goodeve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015;13:1184–95.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Funnell AP, Crossley M. Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet. 2014;30:18–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257:377–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Heit JA, Ketterling RP, Zapata RE, Ordonez SM, Kasper CK, Sommer SS. Haemophilia B Brandenberg-type promoter mutation. Haemophilia. 1999;5:73–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci USA. 2009;106:7921–6.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28:2395–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  1. 1.Department of PediatricsSt. Marianna University School of MedicineKawasakiJapan
  2. 2.Department of PediatricsSt. Marianna University School of Medicine, Yokohama City Seibu HospitalYokohamaJapan
  3. 3.Department of Pathophysiological Laboratory SciencesNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations